Topical and Intralesional Antiviral Agents

Landis, Megan N.

doi:10.1016/b978-0-323-61211-1.00043-7

Cited by 2 publications

(4 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…117 IMI is currently FDA approved for the use of superficial BCC (5% IMI) and AKs (all concentrations). 118 IMI was approved in 2004 for the treatment of superficial BCC after a RCT reported a histologic clearance of 82% for superficial BCC treated topically 5 times per week for 6 weeks. Tumors included in these data were smaller than 2 cm and in low-risk locations.…”

Section: Imiquimodmentioning

confidence: 99%

Immunomodulators for Non-Melanoma Skin Cancers: Updated Perspectives

Russomanno¹,

Azim²,

Patel³

2023

CCID

View full text Add to dashboard Cite

Non-melanoma skin cancers (NMSCs) are the most common cancers worldwide and may be associated with significant morbidity and mortality, especially in immunosuppressed populations. Successful management of NMSC must take primary, secondary and tertiary prevention strategies into consideration. In response to an improved understanding of the pathophysiology of NMSC and associated risk factors, multiple systemic and topical immunomodulatory drugs have been developed and integrated into clinical practice. Many of these drugs are efficacious in the prevention and treatment of precursor lesions (actinic keratoses; AKs), low-risk NMSC, and advanced disease. The identification of patients at high risk for the development of NMSC is critical in reducing disease morbidity. Understanding the various treatment options available and their comparative effectiveness is paramount for developing a personalized treatment regimen for such patients. This review article provides an updated overview of the various topical and systemic immunomodulatory drugs available for the prevention and treatment of NMSC, and the published data supporting their use in clinical practice.

show abstract

Section: Imiquimodmentioning

confidence: 99%

Immunomodulators for Non-Melanoma Skin Cancers: Updated Perspectives

Russomanno¹,

Azim²,

Patel³

2023

CCID

View full text Add to dashboard Cite

show abstract

“… Immunostimulators: Imiquimod is a non-nucleoside heterocyclic amine. [ 7 ] It activates toll-like receptor 7 (TLR-7) and induces secretion of TNF-α, IFN-γ, IFN-α, IL-6, IL-1α, IL-1β, IL-8, IL-12, granulocyte-macrophage colony-stimulating factor (GM-CSF), and granulocyte colony-stimulating factor (G-CSF). [ 7 ] FDA-approved indications include genital warts, actinic keratosis (AK), and basal cell carcinoma (BCC).…”

Section: Introductionmentioning

confidence: 99%

“…[ 7 ] It activates toll-like receptor 7 (TLR-7) and induces secretion of TNF-α, IFN-γ, IFN-α, IL-6, IL-1α, IL-1β, IL-8, IL-12, granulocyte-macrophage colony-stimulating factor (GM-CSF), and granulocyte colony-stimulating factor (G-CSF). [ 7 ] FDA-approved indications include genital warts, actinic keratosis (AK), and basal cell carcinoma (BCC). Other off-label indications are cutaneous warts, molluscum contagiosum, melanoma in situ, herpes simplex,[ 7 ] keloids,[ 2 ] and extramammary Paget’s disease.…”

Section: Introductionmentioning

confidence: 99%

“…[ 7 ] FDA-approved indications include genital warts, actinic keratosis (AK), and basal cell carcinoma (BCC). Other off-label indications are cutaneous warts, molluscum contagiosum, melanoma in situ, herpes simplex,[ 7 ] keloids,[ 2 ] and extramammary Paget’s disease. [ 2 ] Resiquimod is an imidazoquinoline amine[ 8 ] and a potent, soluble analog of imiquimod.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Topical non-steroidal immunomodulators in dermatology

Kadu¹

2023

Indian Dermatol Online J

View full text Add to dashboard Cite

Immunological abnormality is the pathological basis of many dermatological disorders. Although steroids are the backbone of topical therapy in dermatology, the side effects are encountered quite frequently. Thorough knowledge of non-steroidal immunomodulators will broaden our treatment options. A summary of important non-steroidal immunomodulators has been given to help the residents understand the mechanism of action, indications, application, and adverse effects of these drugs.

show abstract

Topical and Intralesional Antiviral Agents

Cited by 2 publications

References 134 publications

Immunomodulators for Non-Melanoma Skin Cancers: Updated Perspectives

Immunomodulators for Non-Melanoma Skin Cancers: Updated Perspectives

Topical non-steroidal immunomodulators in dermatology

Contact Info

Product

Resources

About